JP2015504041A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504041A5
JP2015504041A5 JP2014547490A JP2014547490A JP2015504041A5 JP 2015504041 A5 JP2015504041 A5 JP 2015504041A5 JP 2014547490 A JP2014547490 A JP 2014547490A JP 2014547490 A JP2014547490 A JP 2014547490A JP 2015504041 A5 JP2015504041 A5 JP 2015504041A5
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
composition
subject
enolase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504041A (ja
JP6820653B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/069767 external-priority patent/WO2013090732A2/en
Publication of JP2015504041A publication Critical patent/JP2015504041A/ja
Publication of JP2015504041A5 publication Critical patent/JP2015504041A5/ja
Application granted granted Critical
Publication of JP6820653B2 publication Critical patent/JP6820653B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547490A 2011-12-14 2012-12-14 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 Active JP6820653B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161570366P 2011-12-14 2011-12-14
US61/570,366 2011-12-14
US201261652738P 2012-05-29 2012-05-29
US61/652,738 2012-05-29
PCT/US2012/069767 WO2013090732A2 (en) 2011-12-14 2012-12-14 Collateral gene inactivation biomarkers and targets for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018192504A Division JP7193296B2 (ja) 2011-12-14 2018-10-11 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的

Publications (3)

Publication Number Publication Date
JP2015504041A JP2015504041A (ja) 2015-02-05
JP2015504041A5 true JP2015504041A5 (https=) 2016-02-04
JP6820653B2 JP6820653B2 (ja) 2021-01-27

Family

ID=48613367

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014547490A Active JP6820653B2 (ja) 2011-12-14 2012-12-14 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的
JP2018192504A Active JP7193296B2 (ja) 2011-12-14 2018-10-11 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018192504A Active JP7193296B2 (ja) 2011-12-14 2018-10-11 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的

Country Status (11)

Country Link
US (1) US9452182B2 (https=)
EP (2) EP3603678A3 (https=)
JP (2) JP6820653B2 (https=)
KR (2) KR102144452B1 (https=)
CN (3) CN115177727A (https=)
DK (1) DK2790738T3 (https=)
ES (1) ES2746058T3 (https=)
HR (1) HRP20191607T1 (https=)
HU (1) HUE045359T2 (https=)
IN (1) IN2014DN05803A (https=)
WO (1) WO2013090732A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
CN104894229A (zh) * 2014-03-04 2015-09-09 中南大学 己糖激酶2作为鼻咽癌放疗预后预测的生物标志物
AU2014415566A1 (en) * 2014-12-31 2017-07-20 Develpment Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
PT3268376T (pt) 2015-03-09 2022-04-08 Univ Texas Inibidores de enolase e métodos de tratamento com os mesmos
EP3368687B1 (en) * 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
CA2937896A1 (en) * 2016-08-02 2018-02-02 Universite De Montreal Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia
CN107217054B (zh) * 2017-04-25 2020-08-14 中山大学肿瘤防治中心 G6pd基因及其表达产物在治疗结直肠癌中的应用
CN107460250B (zh) * 2017-09-28 2020-07-28 郑州大学第一附属医院 基于kif14、kif15和kif20a基因的透明细胞肾癌诊断试剂盒及其使用方法
CN113573774B (zh) * 2019-02-26 2026-03-06 诺沃库勒有限责任公司 基于靶向癌细胞的电特性确定TTfield治疗的频率
MX2021011925A (es) * 2019-03-29 2021-11-03 Univ Texas Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano.
EP3976195A4 (en) * 2019-05-28 2023-10-18 The Regents Of The University Of California METHODS OF TREATMENT OF SMALL CELL NEUROENDOCRINAL CANCERS AND ASSOCIATED CANCERS
EP4093513A4 (en) * 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
CN113567675B (zh) * 2020-04-28 2023-09-22 苏州浚惠生物科技有限公司 用于肿瘤的己糖激酶2抑制剂液体活检伴随诊断和试剂盒
EP4225908A1 (en) * 2020-10-06 2023-08-16 European Molecular Biology Laboratory Screening method for the identification of novel therapeutic compounds
WO2023089032A1 (en) * 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023239958A1 (en) * 2022-06-10 2023-12-14 The Children's Hospital Of Philadelphia Alternatively spliced isoform in cancer and methods of use thereof
CN114751961B (zh) * 2022-06-14 2022-09-20 中山大学孙逸仙纪念医院 circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用
CN115074445B (zh) * 2022-08-09 2023-08-08 河北医科大学第二医院 Eno3在肾癌诊断及治疗中的应用
CN115825308B (zh) * 2022-11-30 2023-06-09 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 鼻咽癌相关尿液标志物在制备用于鼻咽癌诊断/预后的产品中的应用
CN116286828B (zh) * 2023-05-12 2023-08-18 中国人民解放军军事科学院军事医学研究院 一种寡聚核酸siRNA及其在制备用于预防和治疗肝癌的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
CA2283636A1 (en) * 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
US6046002A (en) 1998-01-05 2000-04-04 The Board Of Trustees Of The Leland Stanford Junior University Highly parallel and sensitive method for identifying drugs and drug targets
US6200754B1 (en) 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
ATE408593T1 (de) 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
WO2003082187A2 (en) * 2002-03-26 2003-10-09 Indiana University Purification and cloning of nmn adenylyltranserase and its therapeutic use
ATE432097T1 (de) * 2004-08-30 2009-06-15 Interstitial Therapeutics Medizinischer stent mit atp-synthesehemmern
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US8193238B2 (en) 2006-03-08 2012-06-05 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells
US20100189648A1 (en) * 2006-11-02 2010-07-29 Lan Huang Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
CN102225201A (zh) * 2010-05-11 2011-10-26 中国医学科学院基础医学研究所 糖酵解抑制剂的新用途

Similar Documents

Publication Publication Date Title
JP2015504041A5 (https=)
JP6820653B2 (ja) 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的
Chipumuro et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer
Lu et al. LncRNA SNHG16 functions as an oncogene by sponging MiR-4518 and up-regulating PRMT5 expression in glioma
Yan et al. Long noncoding RNA H19/miR-675 axis promotes gastric cancer via FADD/Caspase 8/Caspase 3 signaling pathway
JP2019011365A5 (https=)
Chen et al. miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3
Wu et al. Knockdown of lncRNA MIAT inhibits proliferation and cisplatin resistance in non-small cell lung cancer cells by increasing miR-184 expression
Yoon et al. PHGDH preserves one-carbon cycle to confer metabolic plasticity in chemoresistant gastric cancer during nutrient stress
Pierro et al. The NSD2 p. E1099K mutation is enriched at relapse and confers drug resistance in a cell context–dependent manner in pediatric acute lymphoblastic leukemia
Feng et al. E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2
Sui et al. Propofol suppresses gastric cancer tumorigenesis by modulating the circular RNA-PVT1/miR-195-5p/E26 oncogene homolog 1 axis
Wang et al. Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity
Lim et al. Targeting the PI3K/PTEN/AKT/mTOR pathway in treatment of sarcoma cell lines
Lang et al. Musashi1 promotes non-small cell lung carcinoma malignancy and chemoresistance via activating the Akt signaling pathway
Lailler et al. ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma
Harb-De la Rosa et al. The role of epigenetics in kidney malignancies
Moharram et al. T-cell acute lymphoblastic leukemia cells display activation of different survival pathways
Huang et al. lncRNA DGCR5 inhibits the proliferation of colorectal cancer cells by downregulating miR-21
Zhang et al. MicroRNA‑138 modulates glioma cell growth, apoptosis and invasion through the suppression of the AKT/mTOR signalling pathway by targeting CREB1
Bagaloni et al. Metabolic switch and cytotoxic effect of metformin on Burkitt lymphoma
Wang et al. Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma
Bai et al. Tetraarsenic tetrasulfide triggers ROS-induced apoptosis and ferroptosis in B-cell acute lymphoblastic leukaemia by targeting HK2
Nishioka et al. Imatinib causes epigenetic alterations of PTEN gene via upregulation of DNA methyltransferases and polycomb group proteins
Stachyra et al. Signaling pathways in gliomas